TW200501978A - Use of FGF-18 in the diagnosis and treatment of memory disorders - Google Patents
Use of FGF-18 in the diagnosis and treatment of memory disordersInfo
- Publication number
- TW200501978A TW200501978A TW092133218A TW92133218A TW200501978A TW 200501978 A TW200501978 A TW 200501978A TW 092133218 A TW092133218 A TW 092133218A TW 92133218 A TW92133218 A TW 92133218A TW 200501978 A TW200501978 A TW 200501978A
- Authority
- TW
- Taiwan
- Prior art keywords
- fgf
- treatment
- diagnosis
- memory
- memory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42932102P | 2002-11-26 | 2002-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200501978A true TW200501978A (en) | 2005-01-16 |
Family
ID=32393543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092133218A TW200501978A (en) | 2002-11-26 | 2003-11-26 | Use of FGF-18 in the diagnosis and treatment of memory disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040229292A1 (zh) |
| EP (1) | EP1565204A1 (zh) |
| JP (1) | JP2006516538A (zh) |
| AU (1) | AU2003286285A1 (zh) |
| TW (1) | TW200501978A (zh) |
| WO (1) | WO2004047857A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112772560A (zh) * | 2021-01-07 | 2021-05-11 | 昆明医科大学 | 一种秀丽隐杆线虫对病原细菌遗忘的动物模型的建立方法 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050043234A1 (en) | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| WO2004032849A2 (en) | 2002-10-07 | 2004-04-22 | Zymogenetics, Inc. | Methods of administering fgf18 |
| TW201207390A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Method for screening agent for antidepressant activity |
| EP2327413A1 (en) | 2004-07-06 | 2011-06-01 | ZymoGenetics, Inc. | Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| US7858341B2 (en) | 2004-12-10 | 2010-12-28 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
| KR101347100B1 (ko) | 2005-07-29 | 2014-01-03 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 단독의 또는 pkc 억제제와 배합된 pkc 활성화제의 장기 기억 향상을 위한 용도 |
| JP2007320940A (ja) * | 2006-06-05 | 2007-12-13 | Jichi Medical Univ | 認知症治療剤、認知症治療方法、治療システム、治療装置 |
| CA2673573C (en) | 2007-02-09 | 2016-06-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| WO2008100449A2 (en) * | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| WO2008143880A2 (en) * | 2007-05-24 | 2008-11-27 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury |
| WO2011035192A1 (en) * | 2009-09-21 | 2011-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of gaba-b receptors to enhance neuronal function, learning and memory |
| JP6446624B2 (ja) | 2010-07-08 | 2019-01-09 | アルコン、ダニエル・エル. | 脳卒中の治療法におけるpkc活性化因子および抗凝血剤 |
| AU2016326689A1 (en) * | 2015-09-24 | 2018-03-22 | Genentech, Inc. | Methods for the treatment of epilepsy |
| CN106070014B (zh) * | 2016-06-15 | 2019-06-11 | 哈尔滨商业大学 | 一种基于水迷宫的动物学习记忆的个体化评价方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE493141T1 (de) * | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| JP5209161B2 (ja) * | 1999-12-02 | 2013-06-12 | ザイモジェネティクス, インコーポレイテッド | 腺維芽細胞成長受容体−3又は−2を発現する細胞を標的化するための方法 |
-
2003
- 2003-11-25 US US10/720,091 patent/US20040229292A1/en not_active Abandoned
- 2003-11-26 TW TW092133218A patent/TW200501978A/zh unknown
- 2003-11-26 WO PCT/IB2003/005407 patent/WO2004047857A1/en not_active Ceased
- 2003-11-26 AU AU2003286285A patent/AU2003286285A1/en not_active Abandoned
- 2003-11-26 EP EP03777028A patent/EP1565204A1/en not_active Withdrawn
- 2003-11-26 JP JP2004554841A patent/JP2006516538A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112772560A (zh) * | 2021-01-07 | 2021-05-11 | 昆明医科大学 | 一种秀丽隐杆线虫对病原细菌遗忘的动物模型的建立方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1565204A1 (en) | 2005-08-24 |
| AU2003286285A1 (en) | 2004-06-18 |
| JP2006516538A (ja) | 2006-07-06 |
| US20040229292A1 (en) | 2004-11-18 |
| WO2004047857A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200501978A (en) | Use of FGF-18 in the diagnosis and treatment of memory disorders | |
| Riba et al. | Bringing ayahuasca to the clinical research laboratory | |
| Backhaus et al. | Test–retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia | |
| Friedman et al. | ERP components in picture matching in children and adults | |
| Saletu et al. | EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms: Comparative studies with remoxipride/haloperidol | |
| WO2003075850A3 (en) | Methods for alzheimer's disease treatment and cognitive enhancement | |
| FI971955A7 (fi) | Dopamineeristen solujen indusointi in vitro | |
| WO2005046570A3 (en) | Human stem cell materials and methods | |
| DE60027415D1 (de) | Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält | |
| Thunberg et al. | Gender differences in facial reactions to fear-relevant stimuli | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| EP2357223A3 (en) | Human stem cell material and methods | |
| TR199901304A2 (xx) | Spiro $Piperidin-4,1'-Pirrolo $3,4-c]Pirrol ] | |
| Zhou et al. | Effects of viewing pleasant and unpleasant photographs on facial EMG asymmetry | |
| ATE492285T1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| Schik et al. | Effect of aging on saccadic eye movements to visual and auditory targets | |
| ATE538376T1 (de) | Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke | |
| HUP9701606A2 (hu) | Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására | |
| ATE110277T1 (de) | Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen. | |
| Konno et al. | Effect of gum chewing on PFC activity during discomfort sound stimulation | |
| ATE370416T1 (de) | Neurosteroide als marker für die alzheimersche krankheit | |
| RU94018755A (ru) | Способ диагностики нарушения спинального кровообращения поясничного утолщения | |
| HUP0102116A2 (hu) | Paroxetin-aszkorbát, eljárás az előállítására és gyógyászati alkalmazása | |
| Krystallis | Systematic review of neuromuscular diurnal activity in restless legs syndrome | |
| Shaheen et al. | Effect of Caffeine Consumption on Sleep Quality of Health Professionals of Multan |